Shamburg News · 8-K filed Nov 13, 2026, 5:19 PM EST

Cingulate Reports Q3 2026 Results and Expects CTx-1301 NDA Resubmission by January 2027

CING · Cingulate Inc.

  • Earnings
  • Material agreement
  • Materiality: high

Cingulate Inc. reported a net loss of $7.7 million for the quarter ended September 30, 2026, compared with $7.3 million a year earlier, and approximately $23.2 million in cash and cash equivalents as of September 30, 2026. The company said it substantially completed manufacturing work to address FDA chemistry, manufacturing and controls requests for CTx-1301 and expects to resubmit the NDA between December 2026 and January 2027. On November 13, 2026, the company amended its ATM Sales Agreement with A.G.P. to add Maxim Group LLC as an agent, under which it may sell up to $100,000,000 of common stock.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 2.02, accession 0001493152-26-051841.

Written from the filing by Shamburg Markets. Figures are as reported by the company.